التفاصيل البيبلوغرافية
| العنوان: |
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy |
| المؤلفون: |
Goetz, Matthew P., Sangkuhl, Katrin, Guchelaar, Henk‐Jan, Schwab, Matthias, Province, Michael, Whirl‐Carrillo, Michelle, Symmans, W. Fraser, McLeod, Howard L., Ratain, Mark J., Zembutsu, Hitoshi, Gaedigk, Andrea, van Schaik, Ron H., Ingle, James N., Caudle, Kelly E., Klein, Teri E. |
| المصدر: |
Clinical Pharmacology & Therapeutics ; volume 103, issue 5, page 770-777 ; ISSN 0009-9236 1532-6535 |
| بيانات النشر: |
Wiley |
| سنة النشر: |
2018 |
| المجموعة: |
Wiley Online Library (Open Access Articles via Crossref) |
| الوصف: |
Tamoxifen is biotransformed by CYP2D6 to 4‐hydroxytamoxifen and 4‐hydroxy N‐desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1002/cpt.1007 |
| الإتاحة: |
https://doi.org/10.1002/cpt.1007Test |
| حقوق: |
http://onlinelibrary.wiley.com/termsAndConditions#vorTest |
| رقم الانضمام: |
edsbas.19E26C52 |
| قاعدة البيانات: |
BASE |
